Steris Corporation Receives FDA Clearance For Unique Crossover Surgical Table

Main Category: Medical Devices / Diagnostics
Article Date: 06 Apr 2009 - 2:00 PDT

email to a friend   printer friendly   opinions  

In an ongoing effort to advance healthcare through real-world, practical innovation, STERIS Corporation announces the launch of the revolutionary STERIS 5085 SRT General Surgical Table in North American markets. As the first multi-functional sliding, rotating and transporting table for surgical suites, this practical breakthrough technology balances high quality performance with cost-saving versatility, quality and safety benefits that will help surgical departments improve their productivity and workflow efficiency.

"This transport-capable surgical platform is a radical new concept." states Bill O'Riordan, vice president and general manager of STERIS's surgical business unit. "The STERIS 5085 SRT table is the first FDA-cleared transport-capable surgical platform, and our Customers can use it with confidence. It safely supports, positions, slides, rotates and transports patients, with a single caregiver, throughout the 'red zone.' But this is only the beginning of its capabilities and practical benefits. We expect this table to become the benchmark against which other surgical tables are measured."

The new STERIS 5085 SRT table accommodates everything from advanced imaging procedures and minimally invasive surgical techniques to traditional open surgeries. In the OR, the table's outstanding slide and imaging range virtually eliminates the need for dedicated specialty tables. Its generous weight capacity and height adjustment range assure safe and ergonomic patient support and surgeon access, even for bariatric procedures. And the new intuitive data-rich hand control, central weight-bearing drive wheel and 360° pivot mode help make maneuvering, positioning and transporting patients a smooth, safe and ergonomic process for patients and caregivers.

What's more, the STERIS 5085 SRT Surgical Table performs multiple duties in the surgical department and reduces the risk and time related to patient transfers. The table is designed to support and position the patient from induction, during transport by a single caregiver to the OR, through anesthesia and surgery, and during transport by one person to the recovery area. This provides opportunities for parallel perioperative activities, reduces non-operating time, and helps reduce the number of risky patient transfers in the surgical suite. The STERIS 5085 SRT Surgical Table offers the potential to help hospitals achieve significant gains in workflow efficiency, surgical productivity, and patient and staff safety.

STERIS accessories still apply

The STERIS 5085 SRT General Surgical Table is one of three platforms in the new STERIS series of general surgical tables. These practical innovations offer a range of highly versatile surgical positioning and imaging capabilities, and can be productivity-enhancing solutions for any surgical suite. In addition, all STERIS table accessories for Cmax™ tables that a facility currently owns (with the exception of one headrest) are appropriate for use on the new STERIS 4085, 5085 and 5085 SRT tables.

About STERIS Corporation

STERIS Corporation is a leading provider of infection prevention and surgical products and services, focused primarily on critical healthcare, pharmaceutical and research markets. The Company's more than 5,000 dedicated employees around the world work together to supply a broad array of solutions by offering a combination of equipment, consumables and services that enhance Customer productivity and quality, and help make the world a safer place. The Company is listed on the New York Stock Exchange under the symbol STE.

This news release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry that are intended to qualify for the protections afforded "forward- looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, and changes in government regulations or the application or interpretation thereof. Other risk factors are described in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any future financial results. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications, or the Company's business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, regulations, certifications or other requirements or standards may delay or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, or value, (d) the potential of international unrest or effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, and (f) the possibility that product launch and other expenses may be greater or customer acceptance of the product may not be achieved, or that, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with the matters described in this release may adversely impact Company performance, results, or value.

Source
STERIS Corporation

• Additional
• References
• Citations